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Abstract 
Biologic therapies have shown remarkable efficacy in psoriasis, but individual response varies 
and is poorly understood. To inform biomarker discovery in the Psoriasis Stratification to 
Optimise Relevant Therapy (PSORT) study, we evaluated a comprehensive array of omics 
platforms across three time-points and multiple tissues in a pilot investigation of ten severe 
psoriasis patient, treated with the tumor necrosis factor (TNF) inhibitor, etanercept. We used 
RNA-sequencing to analyse mRNA and small-RNA transcriptomes in blood, lesional and non-
lesional skin and the Somascan platform to investigate the serum proteome. Using an integrative 
systems biology approach, we identified signals of treatment response in genes and pathways 
associated with TNF signalling, psoriasis pathology and the MHC region.  Notably, we found 
association between clinical response and TNF-regulated genes in blood and skin. Using a 
combination of differential expression testing, upstream regulator analysis, clustering techniques, 
and predictive modeling, we demonstrate that baseline samples are indicative of patient response 
to biologic therapies, including signals in blood, which have traditionally been considered 
unreliable for inference in dermatology. In conclusion, our pilot study provides both an 
analytical framework and empirical basis to estimate power for larger studies, specifically the 
ongoing PSORT study, which we demonstrate as powered for biomarker discovery and patient 
stratification. 
 
Introduction 
 
 
The introduction of biologic therapies into clinical practice has led to major improvements for 
patients with severe psoriasis. However, optimal, cost-effective provision of these therapies in a 
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resource-limited healthcare system will necessitate a stratified approach (Griffiths, 2017, 
Lebwohl, 2016).  
Translational research has been revolutionized by the availability of technologies to 
measure features of the genome, transcriptome, and proteome (so called “omics”), primarily 
facilitated by high-throughput sequencing (HTS, formerly next generation sequencing). It is 
likely that data generated by these new technologies will inaugurate an era of stratified care 
founded on comprehensive cellular profiles, rather than individual biomarker molecules 
(Johnston et al., 2017). Such laboratory methods have already been employed in dermatological 
research to identify biomarkers of treatment response in inflammatory skin disease (Correa da 
Rosa et al., 2017, Ungar et al., 2017), but validation of those markers remains elusive and unlike 
our colleagues in oncology, clinical dermatologists have yet to see the integration of omics into 
daily practice. 
Methodological problems have in part hampered the translation of pharmacogenomic 
results into clinical success in dermatology (Jorgensen and Williamson, 2008). Well-designed 
and adequately powered prospective studies are required to identify clinically robust biomarkers. 
Psoriasis Stratification to Optimise Relevant Therapy (PSORT) is an academic-industrial UK 
stratified medicine consortium funded by the Medical Research Council and devoted to 
developing a stratifier of response prediction to biologics , scalable for clinical use for those with 
moderate to severe disease (Griffiths et al., 2015). 
In order to inform the analytical strategy of PSORT, we conducted a pilot study to 
evaluate response to a biologic in psoriasis patients using lesional (PP) and non-lesional (PN) 
skin and blood, and  a range of omic platforms and different analysis pipelines. In addition to 
comparing the performance of each platform and tissue, we used our preliminary data to obtain 
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an empirical estimate of the required sample size to adequately power the full PSORT study. 
Here we report the results of a comprehensive multi-omic pilot study (Figure 1), including RNA 
sequencing (RNA-Seq) of mRNA lesional and non-lesional skin, RNA-Seq from mRNA and 
from miRNA from blood as well as Somascan proteomic data from blood.  
Our tightly phenotyped, rigorously controlled cohort of patients had chronic plaque 
psoriasis and were commencing biologic therapy with the tumor necrosis factor inhibitor (TNFi), 
etanercept. We evaluated the relative merits of each platform and demonstrate a workflow for 
scaled use on large datasets. Novel to pharmacogenomic research in dermatology, we provide 
not only open data but open access to our complete analysis scripts and a fully executable R 
Markdown document for colleagues to evaluate and exactly reproduce the workflow themselves 
(Foulkes et al., 2017). Multi-omic analysis is a highly resource intensive process, particularly 
with the breadth of approaches described here, which are beyond the resources of most projects. 
We use this pilot study to comment on the relative merits of multi-omic approaches and highlight 
platforms that show particular promise in predicting response to therapy.   
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Results 
Patient Characteristics and Analysis of Clinical Response  
Ten patients commencing etanercept therapy were recruited from a prospective clinical 
observational study entitled pharmacogenomic signatures of treatment response in psoriasis. 
Figure 1 provides an overview of the study and patient characteristics for included participants 
are shown in Table 1. Participants were assessed at baseline, week one and week 12 of therapy 
and response to therapy was determined using the Psoriasis Area and Severity Index (PASI), 
with a response defined as a reduction of PASI by at least 75% from baseline (PASI75) and non-
response defined as failure to achieve a reduction of at least 50% from baseline (PASI50). 
Supplementary Figure 2 demonstrates a scatterplot of PASI at baseline vs. PASI at week 12.  
 
Multi-omic analysis 
Using samples from each participant at each time-point (one biopsy sample per library), we 
performed RNA-Seq on mRNA from lesional skin (60m paired reads/sample), non-lesional skin 
(60m paried reads/sample), and blood (30m paired reads/sample). We additionally performed 
RNA-Seq on miRNA from blood (10m single reads/sample) and Somalogic proteomic 
assessment on serum samples. As exploratory data analysis is a key first step in multi-omics, we 
first constructed a sample similarity matrix to compare mRNA transcriptomes across tissues, by 
calculating the pairwise Euclidean distance between all mRNA samples (Supplementary Figure 
2). Samples were clearly separated by tissue, although less distinction was seen between PP and 
PN skin samples, in part reflecting strong intra-subject effects and treatment effects between 
baseline and 12 weeks. Next we examined transcriptome structure on a tissue by tissue basis 
using two different projection methods.  Principal component analysis (PCA) demonstrated clear 
 8 
separation between skin and blood along the first principal component, as expected 
(Supplementary Figure 3a). The second principal component separated lesional from non-
lesional samples, albeit with one data point corresponding to a participant’s week 12 observation. 
This patient showed good response to therapy, suggesting putative detection of remission at 
mRNA transcriptome level. Similar, although less distinct tissue separation was seen by another 
projection method, t-distributed stochastic neighbour embedding (t-SNE) (Supplementary Figure 
3b). Tissue-wise projection plots across all platforms were dominated by intra-subject signatures, 
as anticipated (Supplementary Figures 4 and 5). These unsupervised methods do not appear to 
separate patients by treatment response, indicating that supervised techniques may be required to 
detect a response signal in these data. 
Response differential expression analysis by platform 
Differential expression analyses (DEA) to investigate the effects of etanercept treatment over 
time were performed for each platform (mRNA-Seq, miRNA-Seq and SOMAscan proteomic 
assessment), and tissue type (lesional skin, non-lesional skin and blood) using a common limma 
analytical framework. Access to our complete analysis script and fully executable R Markdown 
document allows reproduction of this workflow with evaluation of these results (see Materials 
and Methods and Supplementary File). We imposed a 10% false discovery rate (FDR) threshold. 
We selected this cut-off because power calculations suggest the modest sample size of the study 
will impede our sensitivity to detect differential expression. A 10% FDR threshold is therefore 
likely to underestimate the true number of differentially expressed genes or proteins in our 
dataset.  
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A summary of differential expression of mRNA, miRNA and protein across time and across 
tissue types may be found in Figure 2, whilst all differentially expressed molecules are 
summarised in supplementary table 1. 
Heatmaps of the top 1% gene expression changes from lesional skin, non-lesional skin, and 
blood are shown in Supplementary Figure 6. The top 1% of genes cluster by response to 
treatment across lesional, non-lesional skin and blood. Similar results were seen with supervised 
and unsupervised cluster assignments. 
  
Upstream regulator analysis 
Acknowledging that our study is not powered for discovery, we used the Upstream Regulator 
Analysis function in Ingenuity Pathway Analysis (IPA) to evaluate upstream regulator signals at 
a systems-level that may be responsible for the observed gene expression changes. Upstream 
regulators are defined as any molecule that can affect the expression of another molecule, 
including transcription factors, cytokines, miRNAs and drugs. The activation state for each 
regulator was predicted based on global direction of changes in the DEA for previously 
published targets of this regulator. The predicted top 30 regulators across all tissues and time 
points are shown in a hierarchically clustered heatmap in Figure 3. Results demonstrate a range 
of pro-inflammatory signalling and drug pathways, including a highly conserved, pan-tissue TNF 
signature, strongest at baseline in blood and at week-1 in lesional and non-lesional skin, and 
substantially diminished at week-12 across all tissues. A similar pattern is also seen in Figure 3 
hierarchically clustered with TNF in Interferon α-2 and γsignalling, in addition to NFΚβ 
signalling. This is an interesting proof of concept of the ability to detect a biologic drug response 
at a systems level which we discuss further below.      
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Platform comparison 
Baseline Omic Platform Concordance 
We performed supervised and unsupervised PAM clustering on baseline samples for each tissue 
across all platforms, relating the differentially expressed genes from each platform to response 
and informing where drivers of prediction to response have commonalities. Cross-platform 
concordance was evaluated using the mutual information between cluster assignments, indicating 
a wide range of concordance values among supervised clusters (Figure 4a). Lesional mRNA and 
blood mRNA concordance was highest at 0.88 bits.  
Machine Learning Models 
We built a series of random forest models to predict continuous response using baseline data 
from each tissue-type and platform (Figure 4b). Predictive power was detected across platforms 
using this methodology, demonstrating additional signal to the differential expression analyses. 
The proteomics assay, in which we found no significant differentially expressed proteins at 
baseline using traditional marginal techniques (i.e., looking at each feature separately), proved 
the most predictive platform for response when modelled using random forests; however 
differences between data types were generally insignificant. The recursive feature elimination 
algorithm we used for these models (see Methods) may provide an alternative approach to 
biomarker discovery, offering new insight into omic signatures of response. Our top performing 
model achieved a RMSE of 0.123, which is just under 75% of the standard deviation of our 
(winsorised) delta PASI distribution.  
Power calculations for a prospective observational study 
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Using the method of Guo et al. (Guo et al., 2014) and parameters derived from this pilot study, 
we calculated the requisite sample size to achieve 90% power to detect differential expression 
associated with response. Using the pilot data presented here as a guide, we project that 17,000 
genes are likely to pass a reasonable expression filter, and that some 1% of these genes will 
prove prognostic in a sufficiently large cohort. The top 1% of genes in our baseline measures had 
an average read count of ~100 prior to normalisation; a minimum log fold change of 
approximately 0.72 after modelling; and a global dispersion estimate of 0.137, as estimated by 
the empirical Bayes procedure of McCarthy et al. (2012). Imposing a 5% FDR threshold and a 
target log fold change of 1.5, we find that a study would require 41 subjects to achieve 90% 
power to identify transcriptomic markers of biologic response for patients with chronic plaque 
psoriasis. Relaxing the number of differentially expressed genes to 5%, we can maintain 90% 
power with 34 subjects. We present power curves projected across an expected range of fold 
changes at 1% and 5% DE in supplementary figure 7.  
 
Discussion 
In this study we present a framework for multi-omic analysis of biologic response. Our results 
are transparent and fully reproducible via companion markdown documents. This makes our 
analysis framework suitable for larger studies of similar nature, such as the PSORT program. We 
emphasise that this proof of concept study is not powered for discovery; however, our results do 
suggest that signals of response to therapy in patients with severe psoriasis treated with the TNFi 
etanercept may be systemically detectable in lesional skin, non-lesional skin and blood at 
baseline, prior to commencement of therapy. Evidence of differential expression correlated with 
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treatment response was observed across all tissue types and time points, but differed across omic 
platforms.   
The choice of the TNFi etanercept related to the timing of study design (in 2010) and the 
observed rates of etanercept response were within the range observed in studies of larger cohorts 
(Leonardi et al., 2003). Prior pharmacogenomic evaluations of patient cohorts have centred on 
the use of genetic or genomic techniques, predominantly  using skin biopsies, although several 
studies have used  skin and blood (Chow et al., 2016, Suárez-Fariñas et al., 2012), with 
consideration of detection of response early in treatment. Whilst no prospective biomarkers have 
yet been validated in adequately powered cohorts, there has been substantial progress, with the 
creation of predictors or classifiers of response (Correa da Rosa et al., 2017). Here, we evaluate 
multiple, complementary omics techniques. We wished to appraise the value of techniques that 
would allow minimally invasive detection of biomarkers of response, including from blood, 
which is routinely taken for patients with severe inflammatory skin disease.  
Our focus was RNA-Seq technology as the gold standard for gene expression profiling. RNA 
sequencing provides counts of all the genes expressed in a sample including microRNAs 
(miRNAs) and other potentially important noncoding RNA species. Use of high quality RNA 
inputs (RIN>8 ensured high quality libraries, which passed relatively stringent QC thresholds. In 
comparison to array-based technologies, RNA-Seq is able to detect low abundance targets; cell-
specific transcripts and alternative splice forms. RNA-Seq is an open platform that is not reliant 
on pre-specified probes and hence it has a capability to identify novel transcripts. We selected 
and RNA-Seq platform to enable direct comparison with other open access research data and to 
data from a future larger validation cohort. RNA-Seq is now becoming the platform of choice for 
transcriptome analysis; especially as costs of HTS techniques reduce over time. RNA-Seq 
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allowed for the same technique to be applied across evaluation of tissue types, and to our 
knowledge forms the first pharmacogenomic assessment using RNA-Seq directly comparing 
samples from lesional skin, non-lesional skin and blood, in addition to proteomics assessment, in 
psoriasis.  We have evaluated a range of exploratory visualisations of our pilot data, which 
showed differing performance, for example a comparison of PCA and t-SNE visualisation of 
lesional vs. non-lesional skin highlighted the former method’s greater sensitivity to local effects. 
 The individual genes identified in differential expression analyses were not further 
evaluated, since our study is not powered for discovery and this approach has been 
comprehensively reported elsewhere (Li et al., 2014).  However, at a systems level, upstream 
regulator analysis (IPA) of DEGs associated with clinical response across tissues and timepoints, 
indicated that changes in genes controlled by the target of the drug, TNF, were the most 
predictive of response. Although this might seem intuitive, previous reports have linked 
etanercept response to interleukin (IL)-17 signaling rather than TNF early response genes (Zaba 
et al., 2009). In blood, in addition to TNF regulation,  we also saw a strong interferon signature 
associated with response to etanercept, which has previously been reported in association with 
etanercept response in skin (Johnston et al., 2014) and also with TNF activation in inflammatory 
diseases (Mavragani et al., 2007, Zou et al., 2003). Comparison of TNF and interferon signatures 
across time points in association with response also shows an interesting pattern, with strong 
signals in blood at baseline, and in skin at 1 week, potentially indicating the genomic response to 
TNFi therapy (Figure 3). Concordance of baseline omic platforms in prediction of response 
demonstrated the strongest association between lesional skin mRNA and blood mRNA. Few 
response associated genes were seen in common across tissues and time points, notably all genes 
associated in more than one tissue were located in the major histocompatibility complex (MHC) 
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(Supplementary Table 1). This correlates with previous genetic findings (Talamonti et al., 2013) 
supporting an immunologic basis to both treatment response and psoriasis pathology (Krueger, 
2002).   
 
Whilst it is difficult to either identify or validate stable subgroups within small cohorts, we are 
confident this approach will be more informative in a larger study and preliminary evidence here, 
suggests that blood biomarkers may be an informative and less invasive predictor of response. 
We used our dataset to empirically inform a power calculation for the prospective study PSORT; 
where 80 participants are being recruited for assessment of each of adalimumab and ustekinumab 
. This demonstrates that the PSORT study is adequately powered to detect moderate to large 
treatment effects in most scenarios.    
We encourage researchers to access our data in ArrayExpress (accession number TK) and 
review our supplementary R Markdown documents on GitHub to learn more about our pipeline 
and to fully reproduce our results. Data sharing and open source analytics are the obvious 
solution to the reproducibility crisis that plagues clinical and omic research today, and is 
becoming more commonplace in fields which are advancing stratified medicine (Omberg et al., 
2013).We believe that open access to data and code should be the norm in life science research, 
not the exception (Foulkes et al., 2017). 
Our study went beyond analysis of a single technology appraisal of treatment prediction 
in one cohort to provide a scalable framework for predictive and inferential analysis of multi-
omic data for clinical dermatology. Despite our small sample size, we were able to detect 
consistent signals of differential expression and build machine-learning models that in 
adequately powered studies, may offer complementary information to clinical factors in the 
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prediction of outcome. We suggest this ability to detect signals  is in part due to the use of a 
single clinician for cohort ascertainment and sample processing thereby  minimising clinical 
confounders and batch issues and allowing bioinformatics expertise to synergise with clinical 
research strategy from conception through analysis. These results have implications for ongoing 
studies. Our exploration has provided the framework for the generation of a large-scale omics 
dataset from PSORT. The signals we have detected will be examined for validity using the same 
robust analytical pipeline in PSORT, which we demonstrate is substantially powered to detect 
true biomarkers of response to therapy. Likewise as omics techniques are applied to other 
dermatological diseases such as atopic eczema (Suarez-Farinas et al., 2015)at the same time as 
an expansion in biologic therapies  is occurring (Blauvelt et al., 2017), genomic approaches to 
personalisation and stratification of therapies may have broad applicability. 
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Materials and Methods 
 
Prospective observational study 
 
Ten participants commencing etanercept therapy (50mg by subcutaneous injection administered 
once weekly) were recruited to take part in a prospective clinical observational study entitled 
‘Pharmacogenomic signatures of treatment response in psoriasis’ (UK Research Ethics 
Committee reference 11/NW/0500; protocol available in supplementary materials). Patients had 
a diagnosis of chronic plaque psoriasis of early onset (≤ 40 years) disease, were White of 
European ancestry (to third generation) and had not received prior systemic or biologic 
treatments in at least two weeks (or four x t½ of last treatment, whichever was longer). Of the 10 
participants, nine were naïve to biologic therapy. Patients completed detailed demographic 
questioning, including reporting information on comorbidities and concomitant medication. 
Disease severity and response to therapy were assessed using the PASI, Physician Global 
Assessment (PGA) and DLQI. Clinical samples including blood and skin biopsies were collected 
at baseline, one week (following the second injection of etanercept) and 12 weeks of treatment. 
Adherence to therapy was assessed, including witnessed/administered injections at the initial 
visit, self-reporting of timings of injections between visits and monitored drug levels at the final 
visit. The same physician and research nurse conducted all research visits (ACF and JH). 
  
 17 
Laboratory methodology 
Skin and blood sampling and RNA extraction 
Samples including lesional and non-lesional skin samples, as well as whole blood, were 
taken at each participant visit. Skin biopsies (6mm punch biopsies) were taken from lesional 
(edge of a plaque) and adjacent (minimum distance of 2cm) non-lesional skin from 
photoprotected sites on the lower back or upper buttock at each visit. Repeat biopsies were taken 
at a minimum distance of 2cm and biopsy sites were recorded. The full laboratory methodology 
is available in Supplementary material. mRNA was extracted from skin biopsies using Qiagen 
Rneasy mini kits. The RNA extraction protocol for skin is provided in the Supplementary 
material. mRNA and miRNA were extracted from blood using miRNeasy blood kits according to 
manufacturers’ protocol. RNA was quantified and quality controlled (assuring a RIN>8) using 
the Agilent RNA 6000 Nano Kit (Agilent Technologies, Waldbronn, Germany) using the 
manufacturer’s protocol.   
RNA Sequencing 
Following quality control, sequencing of mRNA extracted from skin samples was performed at 
GSK, Stevenage and from blood samples at the Centre for Genomic Research, University of 
Liverpool using the Illumina HiSeq 2500 platform. Libraries were prepared with the TruSeq 
Stranded Total RNA Sample Preparation Kits. The first step involved removal of ribosomal 
RNA (rRNA), conducted using biotinylated Ribo-Zero rRNA removal beads. For RNA extracted 
from skin, the Ribo-Zero Gold kit was used to deplete samples of cytoplasmic and mitochondrial 
rRNA. For RNA extracted from blood, the Globin-Zero kit was used to deplete globin-encoding 
mRNA in addition to the rRNA species targeted with Ribo-Zero Gold. The Globin-Zero 
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depletion is essential for removal of the highly abundant adult globin mRNAs from RNA 
extracted from blood samples. 
Somalogic proteomic analysis 
Serum was extracted from whole blood immediately after bleeding and centrifuged at 200g for 7 
minutes, collected into unheparinized centrifugation tubes and kept on ice and at 4°C throughout 
processing.  After separation, serum was snap frozen in liquid nitrogen and stored at -80ºC. 
SOMAmer assays were carried out on 65 microliters of whole serum using standard procedures 
(Somalogic, Boulder, Colorado; PMID: 22022604). The assay used for this study was based on a 
1310 target human protein platform, the complete list is available at the company’s website 
(http://somalogic.com/resources/somascan-assay-support/somamer-reagent-characterization-
data/) and assayed proteins are listed in the proteome data submission (accession: XXX). The 
proteins in this assay panel include cytokines (20%), growth factors (13%), receptors (21%), 
proteases (17%), protease inhibitors (5%), kinases (20%), structural proteins (1%), and hormones 
(3%). 47% of the proteins that are surveyed are secreted proteins, 28% are extracellular domains, 
and 25% are intracellular proteins. 
 
Genomic data analysis workflow 
The RNA-Seq data is available in ArrayExpress (Accession: XXX). The analysis code is 
available in our public GitHub repository (https://github.com/C4TB/markdown-etn_pilot). 
Executable R scripts and R Markdown documents are available as Supplementary files in order 
to allow complete reproduction of our analysis workflow. All analyses were conducted in R 
version 3.4.0. 
Definition of response 
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A positive response to treatment is defined as meeting a PASI 75 (categorical) but continuous 
(linear) models to assess response were also used (see below). One participant was a non-
responder to therapy, determined as not meeting a PASI 50. The ratio of the decrease in PASI to 
the baseline value over 12 weeks is denoted delta PASI and provided a continuous variable for 
modelling of response for differential expression analyses. The non-responder was an extreme 
outlier (more than two and half standard deviations away from the average value of the delta 
PASI distribution) and considering the objective of this study as a pilot for a larger study, we 
elected to impose a cap for minimum and maximum values of two median absolute deviations 
away from the sample median. This process is called Winsorisation, a widely used method for 
adjusting outliers, preferable to trimming when sample sizes are small (Tukey and McLaughlin, 
1963). This changed the delta PASI score for our sole non-responder from -0.05 to 0.37. This 
patient’s results remained the most extreme in our data, but Winsorisation provided a more 
robust response distribution for linear modelling.  
Differential expression analyses 
RNA-sequencing reads were pseudo-aligned using kallisto (Bray et al., 2016) and aggregated to 
gene level with the tximport package (Soneson et al., 2015). Differential expression analyses 
were performed for each platform and tissue type (skin and blood) using the limma software 
package (Smyth, 2004) after read count data had been transformed and precision weighted using 
the voom method (Law et al., 2014). We accounted for the intra-subject correlations inherent to 
our study’s repeated measures design by taking advantage of that software’s duplicate correlation 
function (Smyth et al., 2005). Because library quality varied across samples, we incorporated 
array weights into our voom models (Liu et al., 2015). We employed a robust empirical Bayes 
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shrinkage procedure to mitigate the effects of hypervariable genes (Phipson et al., 2016), and 
estimated FDR using Storey’s q-value method (Storey and Tibshirani, 2003).  
Upstream regulator analysis 
Functional analysis of systems-level upstream regulators responsible for observed differential 
gene expression related to response was performed using the Upstream Regulator function in 
Ingenuity Pathways Analysis (IPA; Ingenuity Systems), using all genes with nominal response p 
 0.05 as input. For all gene set enrichment analyses, a right-tailed Fisher’s exact test was used to 
calculate a pathway p-value determining the probability that each biological function assigned to 
that data set was due to chance alone. All enrichment scores were calculated in IPA using all 
transcripts that passed QC as the background data set. Upstream regulator analysis is based on 
prior knowledge of expected effects between regulators and their known target genes according 
to the IPA database. The prediction of activation state is based on the global direction of changes 
of differentially expressed genes, a z-score is calculated and determines whether gene expression 
changes for known targets of each regulator are correlated with what is expected from the 
literature for an activation of this pathway. In this exploratory analysis we emphasized power 
over type 1 error, using a nominal z score threshold of z > 2 to indicate activation or z < -2 to 
indicate inhibition. 
 
Clustering 
Supervised and unsupervised clusters differ with respect to how genes were filtered across the 
two groupings. For our supervised analysis, we filtered out the bottom half of probes by 
association with biologic response, as determined by moderated t-tests. With unsupervised 
clusters, we filtered by the leading fold change between each sample pair, as implemented in 
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limma (Ritchie et al., 2015). Next, we projected the data in two dimensions using t-SNE (Van 
Der Maaten et al., 2008). Finally, we clustered the samples using k-medoids, also known as the 
PAM algorithm (Kaufman and Rousseeuw, 1990). Ideally, optimal cluster number k would be 
established via a resampling procedure such as consensus clustering (Monti et al., 2003). 
However, given our limited sample size, we chose to fix k = 2, separating samples into two 
groups that would ideally correspond to responders and non-responders. Cross-platform 
concordance was evaluated using the mutual information between cluster assignments, a 
dependency metric that ranges from 0 to 1 bit when k = 2.  
Predictive Models 
We built and evaluated a series of random forest models using continuous response 
measures to compare the predictive power associated with different platforms. To do so, we 
created a pipeline using tools from the caret package for classification and regression training 
(Kuhn and Johnson, 2013).  
Continuous models, designed to predict a patient’s percent change in PASI, were tuned 
using the root mean square error (RMSE) loss function, which is standard for linear regressions. 
Response was defined by a winsorised the delta PASI distribution, as explained above. We 
selected variables using the two-loop RFE algorithm outlined in (Kuhn and Johnson, 2013). For 
each platform, we tested 20 different subsets of probes, with dimensionality determined by an 
exponential function so that relatively low-dimensional subsets of the feature space were 
explored more closely than high-dimensional subsets. Performance was evaluated using 10-fold 
cross-validation. Lower RMSE values indicate more predictive models.  
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Tables and legends 
 
 
Table 1.  
 
Summary of clinical characteristics of included participants 
 
Variable Patients (n = 10) 
Age, mean (years) 43 
Sex F 2, M 8 
Weight, kg (mean ± SD) 94.3 ± 17.7 
BMI (mean ± SD) 30.6 ± 5.5 
Age at onset of psoriasis (years) mean ± SD 17 ± 11 
Baseline PASI; mean ± SD 20.3 ± 8.8 
PASI at week 12; mean ± SD 6.8 ± 3.9 
Baseline DLQI; mean ± SD  20.1 ± 9.3 
DLQI at week 12; mean ± SD 4.5 ± 3.4 
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Figure legends 
 
Figure 1.  
 
Study Overview 
 
Participants were assessed at baseline, week one and week 12 of therapy. Participant sampling 
comprised blood testing, urine collection, lesional and non-lesional skin biopsies (from 
photoprotected sites on the lower back/buttock, from the edge of plaques and at a minimum 
distance from previous biopsy sites). RNA-Seq was conducted on mRNA from blood, lesional 
and non-lesional skin and miRNA from blood. Proteomic assessment was conducted on serum. 
 
Figure 2. 
*Composite figure of below figure and table  
Differential expression of mRNA, miRNA and protein across time and across tissue. 
a)The number of biomolecules declared differentially expressed between responders and non-
responders at 10% FDR for each tissue, time point, and platform. The number of tests vary 
between platforms, mRNA (19304), miRNA (3632), protein (1129) b) Model metrics for random 
forests; we report mean (SD) predictive error and number of features retained after recursive 
feature elimination for each data platform and response type. Continuous response models were 
evaluated using root mean square error (RMSE), while categorical models were tuned with cross 
entropy loss. Asterisks denote the top performing data platform for each class of random forests. 
 
Figure 3 Top upstream regulators across genes differentially expressed in relation to etanercept 
differential expression (p<0.05) response in psoriasis. Top 30 upstream regulators demonstrated. 
The prediction of activation state is based on the global direction of changes of genes with 
differential expression p<0.05. The nominal limit of significance (z-score < -2 or > 2) is 
indicated by the Activation z-score colour scale.  
Figure 4 Concordance of platforms at prediction of PASI 75. a) Heatmap depicting the 
concordance of cluster assignments across platforms as determined by supervised methods.  
b) Box plots demonstrate the distribution of cross-validated root mean square error (RMSE) 
over ten folds for a series of random forests models with recursive feature elimination trained to 
predict the change in PASI using only baseline samples. Lower RMSE values indicate more 
predictive models  
 
 
  
 28 
Supplementary material 
 
Supplementary file: Response analysis markdown document 
 
Supplementary Figure 1. 
Clinical response observed over 12 weeks of TNFi therapy; Baseline PASI vs. PASI at week 12 
of therapy. This figure plots baseline vs. 12 week PASI scores for each patient. The black line 
has an intercept of 0 and a slope of 1, representing zero improvement over the course of 
treatment. The blue line has an intercept of 0 and a slope corresponding to the line of best fit 
through the data points. To obtain a least squares estimate of our study’s average delta PASI, we 
calculate the difference in slope between the black and blue lines: 69%. (The mean of our delta 
PASI distribution is 64%A).  
 
Supplementary Figure 2. Exploratory data analysis of mRNA transcriptome data.  Sample 
similarity matrix depicting samples clustered by pairwise Euclidean distance. 
 
Supplementary Figure 3. Exploratory visualisation of the skin and blood transcriptomes. a) 
Principal component analysis of all skin and blood mRNA samples across all time points, b) t-
stochastic neighbour embedding (t-SNE) clustering of all skin and blood samples across all time 
points. 
 
Supplementary Figure 4. Exploratory visualisation of the psoriasis skin transcriptome.  
a)Principal component analysis of lesional and non-lesional skin mRNA samples; b) t-stochastic 
neighbour embedding (t-SNE)  of mRNA from lesional and non-lesional skin samples 
 
Supplementary figure 5. Exploratory visualisation of blood mRNA and miRNA transcriptomes 
and proteome. a) Principal component analysis (PCA) of mRNA from blood samples; b) PCA of 
miRNA from blood samples; c) PCA of proteome from blood samples; d) t-stochastic neighbour 
embedding (t-SNE) of mRNA from blood samples; e) t-SNE of miRNA from blood samples; f) 
t-SNE of proteome from blood samples. 
 
Supplementary Figure 6. Heatmaps  depicting the top 1% of gene expression changes measured 
by mRNA-Seq in association with the change in PASI in lesional skin (4a), non-lesional skin 
(4b) and blood (4c). Cells are colored by scaled Pearson distance. Annotation tracks atop the 
figures show continuous and categorical response, as well as supervised and unsupervised cluster 
assignments.  
 
Supplementary figure 7. Power curves projected across an expected range of fold changes based 
on the assumption that a) 1% or b) 5% of genes are likely to prove prognostic. Power 
calculations were performed using the method of Guo et al. (2014) and parameters derived from 
this pilot study, we calculated the requisite sample size to achieve 90% power (grey dotted line 
on plot) to detect differential expression associated with response. 
 
Supplementary Table 1. Summary of differential expression of mRNA, miRNA and protein 
(q<0.1) across time and across tissue types (Serum, Blood, Lesional Skin, Non-Lesional Skin) 
 
